Skip to main content
Erschienen in: Inflammation 1/2008

01.02.2008

Etoposide Attenuates Zymosan-Induced Shock in Mice

verfasst von: M. Remichkova, M. Yordanov, P. Dimitrova

Erschienen in: Inflammation | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Zymosan-induced generalized inflammation is a convenient model to study the process of acute and chronic inflammatory processes resulting in multiple organ dysfunction syndrome. Macrophages as a source of many pro-inflammatory mediators are the major players in shock and further organ failure. Etoposide is a cytostatic drug known to reduce macrophages and monocytes in blood circulation. In the present study we have investigated whether the ability of etoposide to diminish macrophage number would have an impact on the course of zymosan-induced shock. The drug injected at a dose of 10 mg/kg 1 day before zymosan, significantly reduced the mortality and decreased the organ toxicity in Balb/c mice. Simultaneously, an inhibition of TNF-α production by alveolar and peritoneal macrophages was observed. Etoposide administered into mice with severe combined immunodeficiency (SCID) did not change the survival rate and had a little influence on organ toxicity. Our findings suggest that the beneficial action of etoposide might be attributed to the reduction of macrophages and alteration of their functions. Its effect depends on the presence of functional T and B lymphocytes. The results deserve further investigation of etoposide as a perspective therapeutic tool for inhibiting the excessive inflammatory response and to be helpful for revealing mechanisms of shock development.
Literatur
1.
Zurück zum Zitat Deitch, E. A. 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9:1–11.PubMedCrossRef Deitch, E. A. 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9:1–11.PubMedCrossRef
2.
Zurück zum Zitat Carpati, C. M., M. E. Astiz, and E. C. Rackow. 1999. Mechanisms and management of myocardial dysfunction in septic shock. Crit. Care. Med. 27:231–232.PubMedCrossRef Carpati, C. M., M. E. Astiz, and E. C. Rackow. 1999. Mechanisms and management of myocardial dysfunction in septic shock. Crit. Care. Med. 27:231–232.PubMedCrossRef
3.
Zurück zum Zitat Karima, R., S. Matsumoto, H. Higashi, and K. Matsushima. 1999. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 5:123–132.PubMedCrossRef Karima, R., S. Matsumoto, H. Higashi, and K. Matsushima. 1999. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 5:123–132.PubMedCrossRef
4.
Zurück zum Zitat Davies, M. G., and P. O. Hagen. 1997. Systemic inflammatory response syndrome. Br. J. Surg. 84:920–935.PubMedCrossRef Davies, M. G., and P. O. Hagen. 1997. Systemic inflammatory response syndrome. Br. J. Surg. 84:920–935.PubMedCrossRef
5.
Zurück zum Zitat Nelson, S. 1999. A question of balance. Am. J. Respir. Crit. Care Med. 159:1365–1367.PubMed Nelson, S. 1999. A question of balance. Am. J. Respir. Crit. Care Med. 159:1365–1367.PubMed
6.
Zurück zum Zitat Goris, R. J., W. K. Boekholtz, I. P. van Bebber, J. K. Nuytinck, and P. H. Schillings. 1986. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch. Surg. 121:897–901.PubMed Goris, R. J., W. K. Boekholtz, I. P. van Bebber, J. K. Nuytinck, and P. H. Schillings. 1986. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch. Surg. 121:897–901.PubMed
7.
Zurück zum Zitat Underhill, D. M. 2003. Macrophage recognition of zymosan particles. J. Endotoxin. Res. 9:176–180.PubMed Underhill, D. M. 2003. Macrophage recognition of zymosan particles. J. Endotoxin. Res. 9:176–180.PubMed
8.
Zurück zum Zitat Meng, G., A. Grabiec, M. Rutz, J. Metzger, P. B. Luppa, H. Wagner, S. Bauer, and C. J. Kirschning. 2005. Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies. Immunol. Lett. 98:200–207.PubMedCrossRef Meng, G., A. Grabiec, M. Rutz, J. Metzger, P. B. Luppa, H. Wagner, S. Bauer, and C. J. Kirschning. 2005. Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies. Immunol. Lett. 98:200–207.PubMedCrossRef
9.
Zurück zum Zitat Sfeir, T., D. C. Saha, M. Astiz, and E. C. Rackow. 2001. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit. Care Med. 29:129–133.PubMedCrossRef Sfeir, T., D. C. Saha, M. Astiz, and E. C. Rackow. 2001. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit. Care Med. 29:129–133.PubMedCrossRef
10.
Zurück zum Zitat von Asmuth, E. J., J. G. Maessen, C. J. van der Linden, and W. A. Buurman. 1990. Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand. J. Immunol. 32:313–319.CrossRef von Asmuth, E. J., J. G. Maessen, C. J. van der Linden, and W. A. Buurman. 1990. Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand. J. Immunol. 32:313–319.CrossRef
11.
Zurück zum Zitat Aldridge, A. J. 2002. Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur. J. Surg. 168:204–214.PubMedCrossRef Aldridge, A. J. 2002. Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur. J. Surg. 168:204–214.PubMedCrossRef
12.
Zurück zum Zitat Baker, C. C., and M. D. Huynh. 1995. Sepsis in the critically ill patient. Curr. Probl. Surg. 32:1013–1083.PubMedCrossRef Baker, C. C., and M. D. Huynh. 1995. Sepsis in the critically ill patient. Curr. Probl. Surg. 32:1013–1083.PubMedCrossRef
13.
14.
Zurück zum Zitat Hande, K. R. 1998. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34:1514–1521.PubMedCrossRef Hande, K. R. 1998. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34:1514–1521.PubMedCrossRef
15.
Zurück zum Zitat Johnson, D. H., J. D. Hainsworth, K. R. Hande, and F. A. Greco. 1991. Current status of etoposide in the management of small cell lung cancer. Cancer 67:231–244.PubMedCrossRef Johnson, D. H., J. D. Hainsworth, K. R. Hande, and F. A. Greco. 1991. Current status of etoposide in the management of small cell lung cancer. Cancer 67:231–244.PubMedCrossRef
16.
Zurück zum Zitat Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7:625–655.PubMed Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7:625–655.PubMed
17.
Zurück zum Zitat Blackwell, T. S., and J. W. Christman. 1996. Sepsis and cytokines: current status. Br. J. Anaesth. 77:110–117.PubMed Blackwell, T. S., and J. W. Christman. 1996. Sepsis and cytokines: current status. Br. J. Anaesth. 77:110–117.PubMed
18.
Zurück zum Zitat Burdon, D., T. Tiedje, K. Pfeffer, E. Vollmer, and P. Zabel. 2000. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit. Care Med. 28:1962–1967.PubMedCrossRef Burdon, D., T. Tiedje, K. Pfeffer, E. Vollmer, and P. Zabel. 2000. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit. Care Med. 28:1962–1967.PubMedCrossRef
19.
Zurück zum Zitat Calame, W., A. E. Douwes-Idema, M. T. van den Barselaar, R. van Furth, and H. Mattie. 1994. Influence of cytostatic agents on the pulmonary defence of mice infected with Klebsiella pneumoniae and on the efficacy of treatment with ceftriaxone. J. Infect. 29:53–66.PubMedCrossRef Calame, W., A. E. Douwes-Idema, M. T. van den Barselaar, R. van Furth, and H. Mattie. 1994. Influence of cytostatic agents on the pulmonary defence of mice infected with Klebsiella pneumoniae and on the efficacy of treatment with ceftriaxone. J. Infect. 29:53–66.PubMedCrossRef
20.
Zurück zum Zitat Calame, W., R. van der Waals, H. Mattie, and R. van Furth. 1989. Influence of etoposide and cyclophosphamide on the efficacy of cloxacillin and erythromycin in an experimental staphylococcal infection. Antimicrob. Agents Chemother. 33:980–982.PubMed Calame, W., R. van der Waals, H. Mattie, and R. van Furth. 1989. Influence of etoposide and cyclophosphamide on the efficacy of cloxacillin and erythromycin in an experimental staphylococcal infection. Antimicrob. Agents Chemother. 33:980–982.PubMed
21.
Zurück zum Zitat Verdrengh, M., O. Isaksson, and A. Tarkowski. 2005. Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis. Rheumatology (Oxford) 44:183–186.CrossRef Verdrengh, M., O. Isaksson, and A. Tarkowski. 2005. Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis. Rheumatology (Oxford) 44:183–186.CrossRef
22.
Zurück zum Zitat Verdrengh, M., and A. Tarkowski. 2003. Impact of topoisomerase II inhibition on cytokine and chemokine production. Inflamm. Res. 52:148–153.PubMedCrossRef Verdrengh, M., and A. Tarkowski. 2003. Impact of topoisomerase II inhibition on cytokine and chemokine production. Inflamm. Res. 52:148–153.PubMedCrossRef
23.
Zurück zum Zitat Nieuwenhuijzen, G. A., M. F. Knapen, T. Hendriks, N. van Rooijen, and R. J. Goris. 1997. Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice. Arch. Surg. 132:533–539.PubMed Nieuwenhuijzen, G. A., M. F. Knapen, T. Hendriks, N. van Rooijen, and R. J. Goris. 1997. Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice. Arch. Surg. 132:533–539.PubMed
24.
Zurück zum Zitat Jansen, M. J., T. Hendriks, M. T. Vogels, J. W. van der Meer, and R. J. Goris. 1996. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit. Care Med. 24:1196–1202.PubMedCrossRef Jansen, M. J., T. Hendriks, M. T. Vogels, J. W. van der Meer, and R. J. Goris. 1996. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit. Care Med. 24:1196–1202.PubMedCrossRef
25.
Zurück zum Zitat Volman, T. J., R. J. Goris, M. van der Jagt, F. A. van de Loo, and T. Hendriks. 2002. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit. Care Med. 30:1553–1559.PubMedCrossRef Volman, T. J., R. J. Goris, M. van der Jagt, F. A. van de Loo, and T. Hendriks. 2002. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit. Care Med. 30:1553–1559.PubMedCrossRef
26.
Zurück zum Zitat Seiter, K. 2005. Toxicity of the topoisomerase II inhibitors. Expert. Opin. Drug Saf. 4:219–234.PubMedCrossRef Seiter, K. 2005. Toxicity of the topoisomerase II inhibitors. Expert. Opin. Drug Saf. 4:219–234.PubMedCrossRef
27.
Zurück zum Zitat Goldmann, O., G. S. Chhatwal, E. Medina. 2005. Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J. Infect. Dis. 191:1280–1286.PubMedCrossRef Goldmann, O., G. S. Chhatwal, E. Medina. 2005. Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J. Infect. Dis. 191:1280–1286.PubMedCrossRef
Metadaten
Titel
Etoposide Attenuates Zymosan-Induced Shock in Mice
verfasst von
M. Remichkova
M. Yordanov
P. Dimitrova
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2008
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-007-9049-8

Weitere Artikel der Ausgabe 1/2008

Inflammation 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.